IQIRVO (Elafibranor) is a medicine used to treat primary biliary cholangitis (PBC).
It’s given along with ursodeoxycholic acid (UDCA) for adults who don’t respond well to UDCA alone, or by itself for those who can’t tolerate UDCA.
It was approved quickly because it lowers alkaline phosphatase (ALP) levels.
However, it’s not yet proven to improve survival or prevent liver problems.
Continued approval depends on further studies showing clear benefits.